Open

Phase 1 Study for PT217

This is a study to learn more about the safety and effectiveness of PT217 to treat advanced cancers. We are looking for patients with small cell lung cancer, large cell neuroendocrine cancer, neuroendocrine prostate cancer or gastroenteropancreatic neuroendocrine carcinomas to take part.

Age & Gender

18 years ~ 99 years
Male, Female

Visit Availability

Standard business hours (M-F, 8-5)

Location

United States (Nationwide)

What will be asked of you

First, you will have a screening visit to make sure you are able to take part. If you can participate, you will receive the drug via an IV during each cycle.

Incentives

Study Medication

Total length of participation:
Until disease progression

Looking for Specific Volunteers

Able to participate:

You have had prior standard of care treatment that did not work
You have a life expectancy of longer than 3 months

Not eligible if:

You have an autoimmune disease requiring systemic treatment within the past twelve months.
You have untreated brain or central nervous system cancer
You have impaired cardiac function
You have uncontrolled high blood pressure
You are pregnant

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Clincal Research
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Jared Weiss
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Phase 1 Trials (all cancers))

IRB Number

23-1716

ClinicalTrials.gov

NCT05652686

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.